Newly released data from the pivotal Phase III trial (TAGS) for trifluridine and tipiracil (TAS-102) showed significant improvement in overall survival (OS) for the treatment of patients with refractory metastatic gastric cancer (HR=0.69 [95% IC...
More From BioPortfolio on "Trifluridine and tipiracil demonstrates overall survival benefit for patients with metastatic gastric cancer"